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Sickle cell anemia is a hematologic disorder impacting over 15 million people worldwide. It is 
caused by a single point mutation in the gene hemoglobin-Betha, where a glu group is replaced 
by val (GAG --- GTG) in the seventh codon (glu7val) of chromosome 1.While healthy 
hemoglobin (HbA) carries oxygen through the blood, mutated hemoglobin (HbS) does the same 
action, but it also goes through polymerization, a chemical process of linking monomers together 
to form polymer chains. Polymerization is one of the key components that causes HbS cells to be 
more likely to stick together in clusters when they are in close proximity, thus blocking the blood 
flow in the human body. Researchers from prior studies have discovered that natural mutations 
reduce polymerization and the sickling properties of the HbS molecules by blocking the 
secondary interactions which impacts the stability of the HbS structure. In this study we are 
comparing the antisickling properties of drugs in varied conditions in order to create a drug that 
is effective in a O2-independent manner and with a 1:1 stoichiometry for lower dosage purposes. 
.  
We compared the main drugs and their respective structures being GBT-440 and VZHE-039. 
Voxelotor is the first aromatic aldehyde with antisickling compounds that target the 
polymerization of Hbs. VZHE-039 binds to Hb in a 2:1 ratio whereas GBT-440  binds with a 1:1 
ratio. The drugs are in an R2 conformation and interact in the same binding site of the 
hemoglobin. The major amino acids it interacts with are: The binding site of the protein are Val 
1, Val 73, Asp 75, Met 76, Pro 77, Asn 78, Ser 131, Thr 134.  GBT-440 and VZHE-039 are both 
aldehydes that inhibit polymerization and antisickling and vary based on the presence of oxygen. 
VZHE-39 is effective in both environments with 2.5% oxygen and no oxygen.  
This study involves combining the oxygen-independent property of VZHE-039 (yellow) and the 
1:1 ratio of GBT-440 (blue) to create a new drug (green) that acts in low and high oxygen 
environments, with low doses. The specific structures responsible for the distinct actions of 





Figure 1: Demonstrates the structure of GBT-440 circling the 









Figure 2: Structure of VZHE-039 and circled methyl hydroxy 







Figure 3: VZHE-039 (yellow) and GBT-440 (blue) represented 
after both PDB structures were superimposed and only the 





Figure 4: New drug structure that consists of the structure of 
GBT-440 and an addition of methyl hydroxy moite in the 








Figure 5: Shows the predicted binding pose of the new drug 
(green).   
 
